Publications by authors named "Thaisa Kowalski Furlan"
Background: Real-world data on the use of Ustekinumab (UST) in Brazilian and Latin American patients with Crohn's disease (CD) are scarce.
Objective: The primary endpoint was assessment of clinical remission at weeks 8 and 52, and secondary endpoints were: assessment of clinical response at weeks 8 and 52, endoscopic remission, adverse events, and rates of CD-related abdominal surgery during follow-up.
Methods: observational and retrospective study, including patients with CD treated at two centers, who received UST at any time during their treatment.
Anti-TNF therapy for ulcerative colitis in Brazil: a comparative real-world national retrospective multicentric study from the Brazilian study group of IBD (GEDIIB).
Ligia Yukie Sassaki Daniela Oliveira Magro Rogerio Saad-Hossne Julio Pinheiro Baima Cristina Flores Thaísa Kowalski Furlan
BMC Gastroenterol
May 2022
Article Synopsis
- Anti-TNF therapy has proven effective in treating ulcerative colitis (UC), but there's limited data on its impact on Brazilian patients; this study compares the efficacy of adalimumab (ADA) and infliximab (IFX) in achieving clinical and endoscopic remission after one year of treatment.
- Conducted across 24 centers, the study included 393 UC patients and utilized various statistical methods to analyze treatment outcomes, finding that IFX showed better clinical remission rates compared to ADA at 26 and 52 weeks.
- Results indicated a clinical remission rate of 82.82% at week 52, with IFX patients experiencing fewer instances of loss of response, although endoscopic remission rates did not significantly differ between the